NYSE - Delayed Quote • USD
Johnson & Johnson (JNJ)
At close: 4:00 PM EDT
After hours: 6:08 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 15 | 15 | 19 | 19 |
Avg. Estimate | 2.53 | 2.52 | 9.94 | 10.21 |
Low Estimate | 2.45 | 2.4 | 9.86 | 9.54 |
High Estimate | 2.65 | 2.61 | 10.13 | 10.76 |
Year Ago EPS | 2.56 | 2.66 | 9.92 | 9.94 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 14 | 14 | 19 | 19 |
Avg. Estimate | 20.79B | 20.72B | 82.44B | 84.65B |
Low Estimate | 20.44B | 20.6B | 82.12B | 82.69B |
High Estimate | 21.1B | 20.84B | 83.33B | 85.69B |
Year Ago Sales | 25.53B | 21.03B | 85.16B | 82.44B |
Sales Growth (year/est) | -18.60% | -1.50% | -3.20% | 2.70% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | 2.62 | 2.52 | 2.28 | 2.46 |
EPS Actual | 2.56 | 2.66 | 2.29 | 2.53 |
Difference | -0.06 | 0.14 | 0.01 | 0.07 |
Surprise % | -2.30% | 5.60% | 0.40% | 2.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 2.53 | 2.52 | 9.94 | 10.21 |
7 Days Ago | 2.72 | 2.69 | 10.66 | 11 |
30 Days Ago | 2.72 | 2.73 | 10.65 | 11.03 |
60 Days Ago | 2.73 | 2.73 | 10.66 | 11.04 |
90 Days Ago | 2.73 | 2.73 | 10.66 | 11.05 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | 2 | 2 | 1 |
Up Last 30 Days | 4 | 4 | 7 | 5 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | -- | 1 | 2 |
Growth Estimates
CURRENCY IN USD | JNJ | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -1.20% | -- | -- | 5.80% |
Next Qtr. | -5.30% | -- | -- | 12.10% |
Current Year | 0.20% | -- | -- | 4.80% |
Next Year | 2.70% | -- | -- | 13.10% |
Next 5 Years (per annum) | 4.88% | -- | -- | 10.96% |
Past 5 Years (per annum) | 5.44% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Upgrade | HSBC: Hold to Buy | 4/18/2024 |
Maintains | RBC Capital: Outperform to Outperform | 4/17/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/17/2024 |
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/17/2024 |
Maintains | B of A Securities: Neutral to Neutral | 4/17/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
Related Tickers
PFE Pfizer Inc.
27.18
+6.09%
ABBV AbbVie Inc.
161.72
-0.57%
MRK Merck & Co., Inc.
128.80
-0.33%
BMY Bristol-Myers Squibb Company
44.21
+0.61%
LLY Eli Lilly and Company
776.75
-0.56%
GILD Gilead Sciences, Inc.
65.51
+0.48%
AMGN Amgen Inc.
277.37
+1.25%
AZN AstraZeneca PLC
76.41
+0.70%
BIIB Biogen Inc.
216.13
+0.61%
GSK GSK plc
42.57
+2.73%